Myositis with anti-NXP2 antibodies

Czech version

Authors: J. Junkerová ^1,2; M. Sabela ^1,2; E. Kovalová ²
Authors‘ workplace: Katedra a centrum klinických neurověd, LF OU, Ostrava ¹; Neurologická klinika FN Ostrava ²
Published in: Cesk Slov Neurol N 2022; 85(2): 185-186
Category: Letters to Editor
doi: https://doi.org/10.48095/cccsnn2022185

Sources

1. Vencovský J. Idiopatické zánětlivé myopatie. Vnitř Lék 2018; 64(2): 155–163.

2. Vencovský J. Idiopatické zánětlivé myopatie – některé novější aspekty. Neurol Praxi 2020; 21(6): 477–484.

3. Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol 2014; 175(3): 349–358. doi: 10.1111/ cei.12194.

4. Rogers A, Chung L,Shufeng L et al. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res 2017; 69(12): 1909–1914. doi: 10.1002/ acr.23210.

5. Inoue M, Tanboon J, Hirakawa S et al. Association of dermatomyositis sine dermatitis with anti-nuclear matrix protein 2 autoantibodies – NXP2. JAMA Neurol 2020; 77(7): 872–877. doi: 10.1001/ jamaneurol.2020. 0673.

6. Butt Z, Patel L, Das MK et al. NXP-2 positive dermatomyositis: a unique clinical presentation. Case Rep Rheumatol 2017; 2017: 4817275. doi: 10.1155/ 2017/ 4817275.

7. Schmidt JJ. Current classification and management of inflammatory myopathies. Neuromuscul Dis 2018; 5(2): 109–129. doi: 10.3233/ JND-180308.

8. Allenbach Y, Benveniste O. Diagnostic Utility of auto antibodies in inflamatory muscle disease. J Neuromuscul Dis 2015; 2(1): 13–25.

9. Yan T, Zhang X, Yang H et al. Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications on a myositis.specific antibody. Clin Rheumatol 2021; 40(9): 3695–3702. doi: 10.1007/ s10067-021-05 667.